Compositions and use of a fibrinogen binding motif present in EFB and COA for therapeutics and vaccines against Staphylococcus aureus

US11407819B2 · kind B2 · utility

Assignees

• THE TEXAS A&M UNIVERSITY SYSTEM · US
• TECHNISCHE UNIVERSITAT BRAUNSCHWEIG · DE
• UNIVERSITA DEGLI STUDI DI PALERMO · IT

Inventors

• Ya-Ping Ko · Sugar Land, US
• Magnus Hook · Houston, US
• Srishtee Arora · Houston, US
• Livia Visai · Rosate, IT
• Federico Bertoglio · Spinadesco, IT
• Michael Hust · Hannover, DE
• Doris Meier · Andreasberg, DE

Key dates

• Filing date: May 20, 2020
• Grant date: Aug 9, 2022
• Expiry date: May 20, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.